A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

<jats:p>Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutral...

Full description

Bibliographic Details
Main Authors: Carter, Brandon, Huang, Pinghan, Liu, Ge, Liang, Yuejin, Lin, Paulo J. C., Peng, Bi-Hung, McKay, Lindsay G. A., Dimitrakakis, Alexander, Hsu, Jason, Tat, Vivian, Saenkham-Huntsinger, Panatda, Chen, Jinjin, Kaseke, Clarety, Gaiha, Gaurav D., Xu, Qiaobing, Griffiths, Anthony, Tam, Ying K., Tseng, Chien-Te K., Gifford, David K.
Other Authors: Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Format: Article
Published: Frontiers Media SA 2023
Subjects:
Immunology
Immunology and Allergy
Online Access:https://hdl.handle.net/1721.1/148458

Internet

https://hdl.handle.net/1721.1/148458

Similar Items